A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy

Breast Cancer Research and Treatment
Andrew RobinsonREaCT investigators

Abstract

All vascular access strategies foradministering chemotherapy in early stage breast cancer (EBC) are associated with risks and benefits. As the most effective type of access is unknown a feasibility trial, prior to conducting a large pragmatic trial, was undertaken. The trial methodology utilized broad eligibility criteria and the integrated consent model incorporating oral consent. EBC patients receiving non-trastuzumab-containing chemotherapy were randomized to peripheral access or central line insertion. The a priori definition of feasibility was: > 25% of patients approached agreed to randomisation and > 25% of physicians approached patients. Secondary outcomes included rates of line-associated complications. Of 159 patients approached, 150 (94.3%) agreed to randomisation, 77 (51.3%) were randomized to peripheral and 73 (48.7%) to central access. 6/26 (23.1%) of medical oncologists approached patients. Rates of complications per chemotherapy cycles in the peripheral vs central access groups with risk difference (RD) (95% CI) were: thrombotic events requiring anticoagulation [1 (0.3%) vs. 3 (1.0%), RD - 0.7(- 1.9,0.5)], line infections [0 (0%) vs. 1 (0.3%), RD - 0.3(- 0.9,0.3)], phlebitis [2 (0.6%) vs. 0 (0%), RD 0.3(- 0.3,0....Continue Reading

References

Sep 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S VesciaN Harbeck
Jul 17, 2009·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Darcy DoellmanMarc Stranz
Oct 12, 2012·Annals of Surgical Oncology·Shayna L ShowalterKathryn H Schmitz
Feb 21, 2014·The New England Journal of Medicine·Scott Y H Kim, Franklin G Miller
May 9, 2014·JAMA : the Journal of the American Medical Association·Jeremy Sugarman, Robert M Califf
Aug 13, 2015·Journal of Oncology Practice·Allison Lipitz-SnydermanJennifer L Malin
Sep 22, 2016·Journal of Oncology Practice·John HiltonMark Clemons

❮ Previous
Next ❯

Citations

Feb 1, 2020·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Mark ClemonsDean Fergusson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.